Allscripts (MDRX) PT Raised to $15 at Piper Jaffray

August 5, 2016 8:10 AM EDT
Get Alerts MDRX Hot Sheet
Price: $17.53 --0%

Rating Summary:
    9 Buy, 18 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 6
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Piper Jaffray analyst Sean Wieland reiterated a Neutral rating but bumped his price target on Allscripts (NASDAQ: MDRX) to $15.00 (from $12.00) following record bookings driven by OptumCare win.

Wieland commented, "Allscripts beat bookings with the announcement of a win at OptumCare, a division of OptumHealth, and is the largest ambulatory deal in the company's History. With this deal in the bag, it was a very solid quarter. We are sticking with our 20x target multiple, however rolling it forward to 2017 estimates, and raising our price target to $15."

For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.

Shares of Allscripts closed at $14.27 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray, Sean Wieland